In the ECHO and THRIVE trials, 10% of the patients who received rilpivirine-based regimens experienced treatment failure. Nearly half of these patients developed resistance to multiple nonnucleoside ...
Discerning the number of individual factors that may contribute collectively to liver damage is difficult in patients receiving antiretroviral therapy. Several drugs are combined in a given HAART ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback